187 related articles for article (PubMed ID: 24847764)
1. Vaccine immunotherapy for prostate cancer: from mice to men.
Lubaroff DM; Vaena D; Brown JA; Zehr P; Griffith KC; Brown E; Eastman J; Nepple K; Kattula A; Williams RD
Immunol Res; 2014 Aug; 59(1-3):229-35. PubMed ID: 24847764
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
3. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.
Lubaroff DM; Konety BR; Link B; Gerstbrein J; Madsen T; Shannon M; Howard J; Paisley J; Boeglin D; Ratliff TL; Williams RD
Clin Cancer Res; 2009 Dec; 15(23):7375-80. PubMed ID: 19920098
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
9. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer.
Lubaroff DM; Konety B; Link BK; Ratliff TL; Madsen T; Shannon M; Ecklund D; Williams RD
Hum Gene Ther; 2006 Feb; 17(2):220-9. PubMed ID: 16454655
[No Abstract] [Full Text] [Related]
10. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer vaccines in clinical trials.
Lubaroff DM
Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
[TBL] [Abstract][Full Text] [Related]
13. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Gulley JL; Madan RA; Tsang KY; Jochems C; Marté JL; Farsaci B; Tucker JA; Hodge JW; Liewehr DJ; Steinberg SM; Heery CR; Schlom J
Cancer Immunol Res; 2014 Feb; 2(2):133-41. PubMed ID: 24778277
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.
Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Br J Cancer; 2004 Aug; 91(4):688-94. PubMed ID: 15280930
[TBL] [Abstract][Full Text] [Related]
15. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
[TBL] [Abstract][Full Text] [Related]
16. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
[TBL] [Abstract][Full Text] [Related]
17. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Gulley JL; Arlen PM; Madan RA; Tsang KY; Pazdur MP; Skarupa L; Jones JL; Poole DJ; Higgins JP; Hodge JW; Cereda V; Vergati M; Steinberg SM; Halabi S; Jones E; Chen C; Parnes H; Wright JJ; Dahut WL; Schlom J
Cancer Immunol Immunother; 2010 May; 59(5):663-74. PubMed ID: 19890632
[TBL] [Abstract][Full Text] [Related]
18. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Gulley JL; Heery CR; Madan RA; Walter BA; Merino MJ; Dahut WL; Tsang KY; Schlom J; Pinto PA
Cancer Immunol Immunother; 2013 Sep; 62(9):1521-31. PubMed ID: 23836412
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]